*** New Vendor Deal – Genuine reta ***

Retatrutide x 10mg x 1 Vial

Retatrutide is a new medication to treat obesity, diabetes, and fatty liver disease.

During the trial phase, people with obesity who took the highest dose in the study lost an average of 17.5% of their starting weight after nearly six months — halfway through. By week 48, subjects lost more than 24% — an average of 58 lbs.

Unsurprisingly, in their June 26, 2023 news release addressing retatrutide trial results, announced improvements in blood pressure and blood glucose, cholesterol, and insulin levels at weeks 24 and 48 of the trial.

Like Wegovy, Mounjaro, and Ozempic, retatrutide helps people lose weight and lower their blood sugar levels. However, Lillys clinical trials also demonstrated a powerful third outcome with retatrutide. Results showed significant improvement in non-alcoholic fatty liver disease (NAFLD), a common and dangerous problem for people with obesity and metabolic syndrome.

Because retatrutide works in three ways, it is considered a tri-agonist.